Search

Displaying results 1811 - 1820 of 8410 in total
  1. Drug

    Vinorelbine

    go.drugbank.com/drugs/DB00361
    ApprovedInvestigational

    Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) [L1998].

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  2. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    [A242572] On November 29, 2021, the FDA approved pafolacianine as an adjunct imaging agent for intraoperative identification of malignant lesions in adult patients with ovarian cancer.

  3. Drug

    Imipenem

    go.drugbank.com/drugs/DB01598
    ApprovedInvestigational

    Similar compounds include [meropenem], known for having greater activity against Gram negative bacteria, and the newer [ertapenem] which exhibits a longer half-life due to increased binding to plasma proteins

    Mixtures: Primaxin IV 250/250 Add-vantage Vial
  4. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    Due to this mutation, all progeny erythrocytes will lack the glycosyl phosphatidylinositol–anchored proteins that normally anchor 2 membrane proteins, CD55 and CD59, that protect blood cells against the

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates
  5. Drug

    Calcifediol

    go.drugbank.com/drugs/DB00146
    ApprovedInvestigationalNutraceutical

    The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores.

    Categories: Vitamin D and AnaloguesSynonyms: 25-Hydroxyvitamin D3
  6. Drug

    PD-168393

    go.drugbank.com/drugs/DB07662
    Experimental

    PD-168393 is an epidermal growth factor receptor inhibitor.

  7. Drug

    Sumanirole

    go.drugbank.com/drugs/DB06477
    Investigational

  8. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency.

  9. Drug

    Salmeterol

    go.drugbank.com/drugs/DB00938
    ApprovedInvestigational

    [A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.[A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542]

    Mixtures: FLUSARION EH50/250UG/60 PC, FLUSARION EH50/500UG/60 PCCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. It has been canceled and withdrawn from the market since August 12, 1997.[L1113]